Boston Scientific (BSX) analysis

Loading the Vaultflake…

Health is the debt of two books, cardiology and endoscopy, not of a patent that lasts forever. Quality separates the margin of one line from the other. Growth follows sales to the hospital, not a launch headline. P/E is read against a year of many launches, not against that peak. Shareholder return, if any, comes out of that cash. Do not read it as organic growth already closed.

The P/E of a year of many launches is not the earnings if the hospital delays the purchase. EV/EBITDA is read without treating one line as if the other could not soften. Do not use Medtronic's multiple, which combines more lines, as if cardiology and that catalog were the same book. A dash if the BSX cache is cold.

Limits of this report

Not advice on Boston Scientific. Vaultflake does not describe how the device is used and does not treat growth as measured. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.

Questions from this report